Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Cytotherapy ; 23(10): 953-959, 2021 10.
Article in English | MEDLINE | ID: mdl-34229963

ABSTRACT

BACKGROUND AIMS: This article describes the development of a small-scale model for Ficoll-based cell separation as part of process development of an advanced therapy medicinal product and its qualification. Because of the complexity of biological products, their manufacturing process as well as characterization and control needs to be accurately understood. Likewise, scale-down models serve as an indispensable tool for process development, characterization, optimization and validation. This scale-down model represents a cell processor device widely used in advance therapies. This approach is inteded to optimise resources and to focus its use on process characterisation studies under the paradigm of the Quality by design. A scale-down model should reflect the large manufacturing scale. Consequently, this simplified system should offer a high degree of control over the process parameters to depict a robust model, even considering the process limitations. For this reason, a model should be developed and qualified for the intended purpose. METHODS: Process operating parameters were studied, and their resulting performance at full scale was used as a baseline to guide scale-down model development. Once the model was established, comparability runs were performed by establishing standard operating conditions with bone marrow samples. These analyses showed consistency between the bench and the large scale. Additionally, statistical analyses were employed to demonstrate equivalence. RESULTS: The process performance indicators and assessed quality attributes were equivalent and fell into the acceptance ranges defined for the large-scale process. CONCLUSIONS: This scale-down model is suitable for use in process characterization studies.


Subject(s)
Biological Products , Ficoll
2.
Aquat Toxicol ; 231: 105718, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33360235

ABSTRACT

Climate change and oil pollution pose a major threat to tropical marine ecosystems and to the coastal communities relying on their resources. The Gulf of Guinea is severely affected by multiple human induced stressors, but the potential impacts of these on marine productivity remain unknown. We investigated the combined effects of heatwaves (climate stressor) and the polycyclic aromatic hydrocarbon pyrene (proxy for oil) on the copepod Centropages velificatus. We quantified survival, reproduction and fecal pellet production of females exposed to concentrations of 0, 10, 100 and 100+ nM (saturated) pyrene under simulated heatwaves of different thermal intensity (+3 °C and +5 °C above control treatment temperature). Thermal stress due to both moderate and intensive heatwaves resulted in reduced survival and egg production. The negative effects of pyrene were only measurable at the high pyrene concentrations. However, thermal stress increased the sensitivity of C. velificatus to pyrene, indicating a synergistic interaction between the two stressors. We document that the interaction of multiple stressors can result in cumulative impacts that are stronger than expected based on single stressor studies. Further research is urgently needed to evaluate the combined impact of climatic and anthropogenic stressors on the productivity of coastal ecosystems, particularly in the tropical areas.


Subject(s)
Climate Change , Petroleum Pollution/analysis , Tropical Climate , Zooplankton/physiology , Animals , Copepoda/drug effects , Copepoda/physiology , Feces , Female , Humans , Pyrenes/toxicity , Reproduction/drug effects , Survival Analysis , Water Pollutants, Chemical/toxicity
3.
J Biol Chem ; 287(34): 28435-44, 2012 Aug 17.
Article in English | MEDLINE | ID: mdl-22761438

ABSTRACT

Polyphosphate (polyP) is a pro-inflammatory agent and a potent modulator of the human blood-clotting system. The presence of polyP of 60 phosphate units was identified in rat basophilic leukemia (RBL-2H3) mast cells using specific enzymatic assays, urea-polyacrylamide gel electrophoresis of cell extracts, and staining of cells with 4,6-diamidino-2-phenylindole (DAPI), and the polyP-binding domain of Escherichia coli exopolyphosphatase. PolyP co-localizes with serotonin- but not with histamine-containing granules. PolyP levels greatly decreased in mast cells stimulated to degranulate by IgE. Mast cell granules were isolated and found to be acidic and decrease their polyP content upon alkalinization. In agreement with these results, when RBL-2H3 mast cells were loaded with the fluorescent calcium indicator fura-2 acetoxymethyl ester to measure their intracellular Ca(2+) concentration ([Ca(2+)](i)), they were shown to possess a significant amount of Ca(2+) stored in an acidic compartment different from lysosomes. PolyP derived from RBL-2H3 mast cells stimulated bradykinin formation, and it was also detected in human basophils. All of these characteristics of mast cell granules, together with their known elemental composition, and high density, are similar to those of acidocalcisomes. The results suggest that mast cells polyP could be an important mediator of their pro-inflammatory and pro-coagulant activities.


Subject(s)
Inflammation Mediators/metabolism , Mast Cells/metabolism , Polyphosphates/metabolism , Animals , Basophils/metabolism , Bradykinin/metabolism , Calcium/metabolism , Cell Line, Tumor , Female , Humans , Lysosomes/metabolism , Male , Rats , Serotonin/metabolism
4.
Haematologica ; 97(8): 1264-71, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22315501

ABSTRACT

BACKGROUND: In hematology there has recently been increasing interest in inorganic polyphosphate. This polymer accumulates in platelet granules and its functions include modulating various stages of blood coagulation, inducing angiogenesis, and provoking apoptosis of plasma cells. In this study we evaluated the characteristics of intracellular polyphosphate in myeloma cell lines, in primary myeloma cells from patients, and in other human B-cell populations from healthy donors. DESIGN AND METHODS: We have developed a novel flow cytometric method for detecting levels of polyphosphate in cell populations. We also used confocal microscopy and enzymatic analysis to study polyphosphate localization and characteristics. RESULTS: We found that myeloma plasma cells contain higher levels of intracellular polyphosphate than normal plasma cells and other B-cell populations. Localization experiments indicated that high levels of polyphosphate accumulate in the nucleolus of myeloma cells. As the principal function of the nucleolus involves transcription of ribosomal DNA genes, we found changes in the cellular distribution of polyphosphate after the inhibition of nucleolar transcription. In addition, we found that RNA polymerase I activity, responsible for transcription in the nucleolus, is also modulated by polyphosphate, in a dose-dependent manner. CONCLUSIONS: Our results show an unusually high accumulation of polyphosphate in the nucleoli of myeloma cells and a functional relationship of this polymer with nucleolar transcription.


Subject(s)
Cell Nucleolus/metabolism , Multiple Myeloma/genetics , Multiple Myeloma/metabolism , Polyphosphates/metabolism , Transcription, Genetic , Antineoplastic Agents/pharmacology , B-Lymphocytes/metabolism , Biological Transport , Cell Line, Tumor , Humans , Leupeptins/pharmacology , Plasma Cells/metabolism , RNA Polymerase I/metabolism , Transcription, Genetic/drug effects
5.
FEBS J ; 276(17): 4828-39, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19664058

ABSTRACT

Factor VII-activating protease (FSAP) circulates as an inactive zymogen in the plasma. FSAP also regulates fibrinolysis by activating pro-urokinase or cellular activation via cleavage of platelet-derived growth factor BB (PDGF-BB). As the Marburg I polymorphism of FSAP, with reduced enzymatic activity, is a risk factor for atherosclerosis and liver fibrosis, the regulation of FSAP activity is of major importance. FSAP is activated by an auto-catalytic mechanism, which is amplified by heparin. To further investigate the structural requirements of polyanions for controlling FSAP activity, we performed binding, activation and inhibition studies using heparin and derivatives with altered size and charge, as well as other glycosaminoglycans. Heparin was effective in binding to and activating FSAP in a size- and charge density-dependent manner. Polyphosphate was more potent than heparin with regard to its interactions with FSAP. Heparin was also an effective co-factor for inhibition of FSAP by plasminogen activator inhibitor 1 (PAI-1) and antithrombin, whereas polyphosphate served as co-factor for the inhibition of FSAP by PAI-1 only. For FSAP-mediated inhibition of PDGF-BB-induced vascular smooth muscle cell proliferation, heparin as well as a polyphosphate served as efficient co-factors. Native mast cell-derived heparin exhibited identical properties to those of unfractionated heparin. Despite the strong effects of synthetic polyphosphate, the platelet-derived material was a weak activator of FSAP. Hence, negatively charged polymers with a high charge-to-size ratio are responsible for the activation of FSAP, and also act as co-factors for its inhibition by serine protease inhibitors.


Subject(s)
Factor VIIa/chemistry , Heparin/chemistry , Polyphosphates/chemistry , Serine Endopeptidases/chemistry , Animals , Antithrombins/chemistry , Becaplermin , Catalytic Domain , Cell Proliferation , Cells, Cultured , Enzyme Activation , Factor VIIa/antagonists & inhibitors , Factor VIIa/metabolism , Heparin/metabolism , Heparin/pharmacology , Heparitin Sulfate/metabolism , Heparitin Sulfate/pharmacology , Humans , Mice , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/physiology , Plasminogen Activator Inhibitor 1/chemistry , Platelet-Derived Growth Factor/metabolism , Polyphosphates/metabolism , Protein Binding , Proto-Oncogene Proteins c-sis , Serine Endopeptidases/metabolism
6.
J Proteome Res ; 6(11): 4449-57, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17918986

ABSTRACT

Dense granules, a type of platelet secretory organelle, are known to accumulate high concentrations of small molecules such as calcium, adenine nucleotides, serotonin, pyrophosphate, and polyphosphate. Protein composition of these granules has been obscure, however. In this paper, we use proteomics techniques to describe, for the first time, the soluble protein composition of platelet dense granules. We have isolated highly enriched human platelet dense granule fractions that have been analyzed using two proteomics methods. Using this approach, we have identified 40 proteins, and most of them, such as actin-associated proteins, glycolytic enzymes, and regulatory proteins, have not previously been related to the organelle. We have focused our efforts on studying 14-3-3zeta, a member of a conserved family of proteins that interact with hundreds of different proteins. We have demonstrated that 14-3-3zeta is localized mostly on dense granules and that it is secreted after platelet activation. As some proteins secreted from activated platelets could promote the development of atherosclerosis and thrombosis, we have studied the expression of 14-3-3zeta in sections of human abdominal aorta of patients with aneurysm, identifying it at the atherosclerotic plaques. Together, our results reveal new details of the composition of the platelet dense granule and suggest an extracellular function for 14-3-3zeta associated with atherosclerosis.


Subject(s)
14-3-3 Proteins/biosynthesis , 14-3-3 Proteins/physiology , Atherosclerosis/metabolism , Blood Platelets/metabolism , Proteomics/methods , Aortic Aneurysm, Abdominal/metabolism , Chromatography, Liquid/methods , Electrophoresis, Gel, Two-Dimensional , Electrophoresis, Polyacrylamide Gel , Glycolysis , Humans , Microscopy, Fluorescence , Models, Biological , Platelet Activation , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Subcellular Fractions
7.
Haematologica ; 91(9): 1180-6, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16956816

ABSTRACT

BACKGROUND AND OBJECTIVES: Inorganic polyphosphate (polyP), a ubiquitous phosphate polymer with ATP-like bonds, has recently been related to a variety of functions including blood coagulation and cell proliferation. We investigated the effects of polyP in the biology of human plasma cells (PC), responsible for the production and maintenance of antibodies in response to antigens. DESIGN AND METHODS: The U266 myeloma cell line was used to study whether polyP affects immunoglobulin (Ig) secretion and survival. Different human cell lines were used to test the specificity of polyP on viability. We analyzed Ig secretion of PC from bone marrow and peripheral blood after polyP addition. A conventional tetanus toxoid booster immunization was used to increase the proportion of PC in order to examine the ex vivo effects of polyP. We also tested the effects of polyP on primary myeloma cells. Ig secretion and apoptosis were determined by ELISA and FACS respectively. RESULTS: Addition of polyP to human PC produced an unexpected inhibition of Ig secretion and stimulation of apoptosis. PolyP generated apoptosis specifically in PC, myeloma (malignant PC) cell lines, primary myeloma cells, and B lymphoid cell lines. Normal B cells, T cells, total blood mononuclear cells, and non-lymphoid cell lines were not affected by polyP. In the U266 myeloma cell line, polyP induced externalization of phosphatidylserine, activation of caspase-3, and arrest of the cell cycle. The protective effects of interleukin-6 did not overcome the polyP-induced apoptosis Interpretation and CONCLUSIONS: Taken together, our results suggest for the first time the relevance of the use of polyP to the humoral immune response and open prospects for polyP as a novel therapy for myeloma.


Subject(s)
Apoptosis/drug effects , Plasma Cells/cytology , Polyphosphates/pharmacology , Bone Marrow , Cell Line , Cell Line, Tumor , Cell Survival/drug effects , Humans , Immunoglobulins/metabolism , Plasma Cells/drug effects , Plasma Cells/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...